BACKGROUND: Despite their efficacy in the treatment of benign prostatic hyperplasia (BPH) the popularity of inhibitors of 5α-reductase (5ARI) is limited by their association with adverse sexual side effects. However, the real impact of 5ARI on sex hormones and sexual function is controversial. AIM: To investigate the role of 5ARI therapy on hormonal parameters and sexual function in men already complaining of sexual problems. MATERIALS AND METHODS: A consecutive series of 3837 men (mean age 63.5±12.8 yr) attending our outpatient clinic for sexual dysfunction was retrospectively studied. Several clinical, biochemical, and instrumental (penile color doppler ultrasound) factors were evaluated. RESULTS: Among the patients studied, 78.7% reported erectile dysfunction, 51.1% hypoactive sexual desire (HSD), 86.7% perceived reduced sleep-related erections (PR-SRE) and 19.1% premature ejaculation. The use of 5ARI was associated with an increased risk of HSD and PR-SR whereas no relationship was found with erectile dysfunction and ejaculation disturbances. Subjects using 5ARI also more frequently had gynecomastia along with reduced SHBG and higher calculated free testosterone levels. All these associations were confirmed in a case-control study comparing 5ARI users with age-body mass index-smoking status and total testosterone-matched controls. CONCLUSIONS: Our data indicates that use of 5ARI in men with sexual dysfunction does not significantly exacerbate pre-existing ejaculatory or erectile difficulties, but can further impair their sexual life by reducing sexual drive and spontaneous erection.
BACKGROUND: Despite their efficacy in the treatment of benign prostatic hyperplasia (BPH) the popularity of inhibitors of 5α-reductase (5ARI) is limited by their association with adverse sexual side effects. However, the real impact of 5ARI on sex hormones and sexual function is controversial. AIM: To investigate the role of 5ARI therapy on hormonal parameters and sexual function in men already complaining of sexual problems. MATERIALS AND METHODS: A consecutive series of 3837 men (mean age 63.5±12.8 yr) attending our outpatient clinic for sexual dysfunction was retrospectively studied. Several clinical, biochemical, and instrumental (penile color doppler ultrasound) factors were evaluated. RESULTS: Among the patients studied, 78.7% reported erectile dysfunction, 51.1% hypoactive sexual desire (HSD), 86.7% perceived reduced sleep-related erections (PR-SRE) and 19.1% premature ejaculation. The use of 5ARI was associated with an increased risk of HSD and PR-SR whereas no relationship was found with erectile dysfunction and ejaculation disturbances. Subjects using 5ARI also more frequently had gynecomastia along with reduced SHBG and higher calculated free testosterone levels. All these associations were confirmed in a case-control study comparing 5ARI users with age-body mass index-smoking status and total testosterone-matched controls. CONCLUSIONS: Our data indicates that use of 5ARI in men with sexual dysfunction does not significantly exacerbate pre-existing ejaculatory or erectile difficulties, but can further impair their sexual life by reducing sexual drive and spontaneous erection.
Authors: F M Debruyne; A Jardin; D Colloi; L Resel; W P Witjes; M C Delauche-Cavallier; C McCarthy; C Geffriaud-Ricouard Journal: Eur Urol Date: 1998-09 Impact factor: 20.096
Authors: John K Amory; Christina Wang; Ronald S Swerdloff; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; Susan E Walker; Lynda J Haberer; Richard V Clark Journal: J Clin Endocrinol Metab Date: 2007-02-13 Impact factor: 5.958
Authors: G J Gormley; E Stoner; R C Bruskewitz; J Imperato-McGinley; P C Walsh; J D McConnell; G L Andriole; J Geller; B R Bracken; J S Tenover Journal: N Engl J Med Date: 1992-10-22 Impact factor: 91.245
Authors: G Corona; L Petrone; E Mannucci; E A Jannini; R Mansani; A Magini; R Giommi; G Forti; M Maggi Journal: Eur Urol Date: 2004-11 Impact factor: 20.096
Authors: F Borgo; A D Macandog; S Diviccaro; E Falvo; S Giatti; G Cavaletti; R C Melcangi Journal: J Endocrinol Invest Date: 2020-09-19 Impact factor: 4.256
Authors: Jae Heon Kim; Min Jung Baek; Hwa Yeon Sun; Bora Lee; Shufeng Li; Yash Khandwala; Francesco Del Giudice; Benjamin I Chung Journal: PLoS One Date: 2018-10-03 Impact factor: 3.240
Authors: A Sansone; S Kliesch; M Dugas; R Sandhowe-Klaverkamp; A M Isidori; S Schlatt; M Zitzmann Journal: J Endocrinol Invest Date: 2021-04-03 Impact factor: 4.256